Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
NCT ID: NCT00880347
Last Updated: 2011-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
550 participants
INTERVENTIONAL
2008-02-29
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alzheimer's Disease
Group of patients clinically diagnosed with probable AD
Blood sampling
Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
Non-AD dementia
Group of patients clinically diagnosed with one of the 5 most frequent non-AD dementia : vascular dementia, mixed dementia, frontotemporal dementia, Lewy bodies dementia, Parkinson's disease dementia.
Blood sampling
Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
control subjects
Group of control subjects without any clinical cognitive impairment.
Blood sampling
Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling
Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female patient, aged ≥ 40 years old included at entry.
* Patients having a clinical diagnosis of probable AD according to DSM-IV TR \[F00.xx\] and National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
* Written informed consent obtained from the patient or, if appropriate, from legal representative according to local laws and regulations.
* Evidence that brain imaging (either cerebral CT-scan or cerebral MRI) was performed to settle the AD diagnosis, and that the results are compatible with AD diagnosis.
* Neurological exam without any particularities or without any specific focal signs likely to be related to other conditions than AD.
* Patient compliant with study procedures.
2. Non AD demented group :
* Male or female patient, aged ≥ 40 years old included at entry.
* Patients having a clinical diagnosis of dementia which can be one of the following :
* VaD according to NINDS-AIREN criteria or,
* LBD according to McKeith's criteria, or,
* FTD according to Neary's or Lund \& Manchester criteria or,
* PDD according to DSM-IV TR criteria \[F02.x\] or,
* Mixed dementia which is defined in this study as patients fulfilling DSM-IV TR criteria \[F02.8\] for dementia with multiple aetiologies focussing on dementia of Alzheimer type with secondary occurrence of vascular dementia.
* Written informed consent obtained from the patient or, if appropriate, from legal representative according to local laws and regulations.
* Evidence that brain imaging (either cerebral CT-scan or cerebral MRI) was performed to settle the diagnosis of dementia, and that the results are compatible with the diagnosis of dementia.
* Absence of other signs or symptoms that may be better related to another type of dementia than the current dementia diagnosis.
* Patient compliant with study procedures.
3. Cognitive impairment-free control group :
* Male or female subject, aged ≥ 60 years old included at entry.
* Written informed consent obtained from the subject.
* Absence of spontaneously reported significant cognitive complaints from the subject at entry.
* MMSE ≥ 27 at entry.
* Subject with no impairment in daily living activities.
* Subject compliant with study procedures.
Exclusion Criteria
* Any pathology, medical condition or symptoms that may lead to reconsider the initial diagnosis of probable AD, or that may rend the initial diagnosis of probable AD doubtful at entry, according to the opinion of the investigator.
* Current or recent history of drug or alcohol abuse or dependence.
* Diagnostic of Mild Cognitive Impairment defined by subjective complaints from the patient regarding memory and/or cognitive symptoms, objective memory and/or cognitive impairment at testing but not meeting AD diagnostic criteria, and not affecting daily living activities.
* Current diagnosis of brain tumour.
* Any current pathology or medical condition, for which blood sampling may involve a risk for the patient's health, according to the opinion of the investigator.
* Pregnancy.
* Patient who is not registered at "Sécurité Sociale".
* Current participation in another study using an investigational non-marketed product.
2. Non-AD demented group :
* Any pathology, medical condition or symptoms that may lead to reconsider the initial diagnosis of dementia the patient is suffering from, or that may rend the initial diagnosis of dementia doubtful at entry, according to the opinion of the investigator.
* Diagnostic of Mild Cognitive Impairment defined by subjective complaints from the patient regarding memory and/or cognitive symptoms, objective memory and/or cognitive impairment at testing but not meeting the diagnostic criteria for dementia, and not affecting daily living activities.
* Current diagnosis of brain tumour.
* Any current pathology or medical condition for which blood sampling may involve a risk for the patient's health, according to the opinion of the investigator.
* Current or recent history of drug or alcohol abuse or dependence.
* Pregnancy.
* Patient who is not registered at "Sécurité Sociale".
* Current participation in another study using an investigational non-marketed product.
3. Cognitive impairment-free control group :
* Subject spontaneously complaining from significant cognitive impairment.
* Known family history of dementia.
* Diagnosis of any type of dementia (either AD or non-AD dementia), Mild Cognitive Impairment, or any current or past history of CNS pathology (including but not limited to brain injury, brain tumour, stroke, normal pressure hydrocephalus, Parkinson's disease, epilepsy, multiple sclerosis,…) that may be responsible for the occurrence of dementia.
* History or current clinically significant psychiatric pathology (including but not limited to psychotic disorders, bipolar disorder, personality disorders).
* Current major depressive disorder, either treated or not, associated with clinically significant symptoms.
* Any current pathology or medical condition for which blood sampling may involve a risk for the subject's health, according to the opinion of the investigator.
* Current or recent history (within one month) of clinically significant pathology, medical condition (including hospitalization) or symptoms. However, chronic diseases or medical conditions which are considered stable are accepted, provided that they are compatible with other study selection criteria.
* Current or recent history of drug or alcohol abuse or dependence.
* Subject who is not registered at "Sécurité Sociale".
* Current participation in another study using an investigational non-marketed product.
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Exonhit
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Toulouse - Purpan - Casselardit Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olivier SOL, MD
Role: STUDY_DIRECTOR
Exonhit
Bruno Vellas, MD
Role: PRINCIPAL_INVESTIGATOR
Purpan- Casselardit Hospital - Toulouse University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Privé Les Magnolias
Ballainvilliers, , France
Cabinet Médical
Bergerac, , France
Centre Médical
Dijon, , France
Cabinet Médical
La Seyne-sur-Mer, , France
Cabinet Médical
Le Vésinet, , France
Clinique Léopold Bellan
Magnanville, , France
Cabinet Médical
Marseille, , France
Centre Médical
Montpellier, , France
Cabinet Médical
Montpellier, , France
CMRR Gui de Chauliac Hospital
Montpellier, , France
CHU Nantes Hôpital Laennec
Nantes, , France
ClinOuest network
Nantes, , France
Cabinet Médical 2
Nice, , France
Cabinet Médical
Nice, , France
Cabinet Médical
Paris, , France
Centre Médical
Rambouillet, , France
Cabinet Médical
Rodez, , France
Cabinet Médical
Rueil-Malmaison, , France
Cabinet Médical
Saint-Brieuc, , France
Purpan-Casselardit Hospital - University of Toulouse
Toulouse, , France
CDPRV Le Capitole
Valence, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EHTAD/002
Identifier Type: -
Identifier Source: org_study_id